GOG Foundation GOG-3127 / AstraZeneca D8891C0001 (TREVI)

Trial Overview

Official Title

A Randomized, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)

Study Purpose

To find out about the safety and efficacy (how well a drug works) of AZD5335 for the treatment of platinum-resistant ovarian cancer by comparing AZD5335 to standard of care therapies.

Diagnosis

Platinum resistant recurrent ovarian cancer

Eligibility

High-grade serous epithelial ovarian/fallopian tube/primary peritoneal cancer, 1-3 prior lines of systemic treatment, FOLR1 ≥ 25%, prior treatment with bevacizumab and PARP inhibitor if eligible.

Intervention

FOLR1 ≥ 75%: AZD5335 vs. Mirvetuximab. FOLR1 ≥ 25% but < 75%: AZD5335 vs. investigator’s choice chemotherapy.

For more information, click the link below:

https://clinicaltrials.gov/study/NCT07218809?intr=Trevi&rank=1

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Female
Age
19 years and older
Enrollment Status
Recruiting
Phase
Phase III
Methodist Health System Trial Code
GOG-3127